Welcome to our dedicated page for Inspiremd SEC filings (Ticker: NSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InspireMD, Inc. (NSPR) files reports with the U.S. Securities and Exchange Commission as a Nasdaq-listed medical device company focused on the CGuard® Prime carotid stent system and its proprietary MicroNet™ mesh technology. These SEC filings provide detailed information on the company’s financial condition, capital structure, clinical and regulatory milestones, and governance.
Current reports on Form 8-K frequently disclose key events such as quarterly financial results, private placement financings, warrant exercises, and updates to investor presentations. For example, a November 4, 2025 Form 8-K discusses financial and operating results for the quarter ended September 30, 2025, while a July 31, 2025 Form 8-K outlines a securities purchase agreement for a private placement of common stock and pre-funded warrants, as well as the full exercise of a series of warrants.
Filings also document important regulatory and commercial milestones. A June 24, 2025 Form 8-K reports that InspireMD received FDA premarket approval (PMA) for the CGuard Prime Carotid Stent System in the United States, and a July 9, 2025 Form 8-K references a press release announcing the U.S. commercial launch of CGuard® Prime. Other 8-Ks describe changes to the board of directors, including the appointment of independent directors and audit committee chairs, and amendments that specify committee assignments.
On this page, users can review InspireMD’s Forms 8-K and related exhibits, along with other periodic reports when available. Stock Titan adds AI-powered summaries that explain the main points of lengthy filings, highlight material agreements and capital-raising terms, and surface notable disclosures about clinical and regulatory developments. Investors and researchers can use these NSPR filings to understand how InspireMD reports its progress in carotid stenting, manages its capital resources, and addresses the risks and uncertainties outlined in its forward-looking statements.
Rosalind Advisors, Inc. and affiliated funds disclose aggregate beneficial ownership of 10,987,104 shares of InspireMD, Inc., equal to 9.9% of the 41,720,662 shares used for the calculation. The reported position combines 3,905,743 currently outstanding common shares and 7,081,361 shares issuable upon exercise of warrants as reflected on the cover pages.
The filing notes that the warrants include blocker provisions preventing exercise to the extent such exercise would raise beneficial ownership above 9.99%, so the actual exercisable shares are limited. The Schedule 13G/A is certified and signed by the reporting persons on 08/11/2025.
Rosalind Advisors and affiliated funds report shared beneficial ownership in InspireMD (NSPR), including common shares and warrants that together total 10,987,104 securities representing 9.4% of the class as stated on the cover page. The holding is shown as 3,905,743 common shares plus 7,081,361 shares issuable on warrants for the Advisor group, while Rosalind Master Fund L.P. reports 3,508,336 common and 5,977,361 warrant-issuable shares, and Rosalind Opportunities Fund I L.P. reports 397,407 common and 1,104,000 warrant-issuable shares. The filing notes that blocker provisions limit exercise of some warrants, so the actual exercisable ownership is lower than the raw totals. The Advisor and certain principals disclaim beneficial ownership of shares held by advised funds.
Rosalind Advisors, related funds and principals report material holdings in InspireMD (NSPR). The filing shows aggregate beneficial positions reported as 10,987,104 shares for several Reporting Persons, which the filing presents as approximately 9.4% of the class based on the S-3 share count and other per-entity percentages (Rosalind Master Fund L.P. 9.485,697 shares / 8.4%; Rosalind Opportunities Fund I L.P. 1,501,407 shares / 0.9%).
The reported totals include both currently outstanding common shares and shares issuable upon exercise of warrants (for example, Rosalind Advisors reports 3,905,743 common shares plus 7,081,361 shares issuable on warrants). The filing also discloses blocker provisions that prevent exercise of warrants to the extent doing so would push beneficial ownership above 9.99%, so the practical exercisable interest is lower than the raw issuable amount. The filing includes a certification that the holdings are held in the ordinary course of business and not for the purpose of changing control.
InspireMD, Inc. filed an 8-K dated August 5, 2025 reporting that it issued a press release with financial and operating results for the three and six months ended June 30, 2025 (Item 2.02) and made an updated investor presentation available (Item 7.01).
The filing states the press release is attached as Exhibit 99.1 and the investor presentation as Exhibit 99.2, and that both are furnished (not "filed") under General Instruction B.2. The presentation is available on the company website at https://www.inspiremd.com/en/investors/. This 8-K does not include the underlying financial figures; readers must consult the attached exhibits for results.